P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS

ABSTRACT:

SUBMITTER: Abraham P 

PROVIDER: S-EPMC9430144 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature